COMMUNIQUÉS West-GlobeNewswire

Amedisys Reports Fourth Quarter and Year End 2018 Financial Results Issues 2019 Guidance
27/02/2019
BATON ROUGE, La., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three month period and year ended December 31, 2018. Three Month Periods Ended December 31, [...]
Canopy Rivers Reports Third Quarter Financial Highlights and Provides Current Corporate Update
27/02/2019
TORONTO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (the “ Company ” or “ Canopy Rivers ”) (TSXV: RIV) today released its financial results for the three and nine months ended December 31, 2018. The Company’s [...]
New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Annual Meeting 2019
27/02/2019
Presentations will feature data on 1) CD38-targeted ETB TAK-169, 2) CD20-targeted ETB MT-3724 in combination with chemotherapy or IMiDs, 3) PD-L1-targeted ETB for direct cell kill approach to PD-L1 expressing cancers, 4 [...]
LHC Group Announces Fourth Quarter 2018 Financial Results
27/02/2019
2019 Guidance Highlights Strong Earnings Accretion from Almost Family Acquisition and Contributions from Joint Ventures LAFAYETTE, La., Feb. 27, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc. (NASDAQ: LHCG) announced its [...]
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting
27/02/2019
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting
27/02/2019
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE [...]
Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019
27/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the [...]
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
27/02/2019
CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular [...]
Guardant360 Performance Matches Standard-of-Care Tissue Testing in First-Line, Advanced Non-Small Cell Lung Cancer, NILE Study Shows, Meeting Primary Endpoint
27/02/2019
Head-to-Head Comparison to be Presented at AACR Supports Use of “Blood First” For First-Line Advanced NSCLC Patients REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announced [...]
iCAD to Partner with Leading Breast Cancer Researchers from Karolinska Institutet to Develop Artificial Intelligence-Based Breast Cancer Risk Prediction Solution
27/02/2019
Proposed Collaboration would support iCAD’s leadership position in providing AI-based solutions that advance risk assessment for breast cancer VIENNA, Austria, Feb. 27, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD [...]
NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
27/02/2019
AMES, Iowa, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a nanoparticle formulation of the [...]
Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
27/02/2019
-- Initiated multiple-ascending dose portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis -- -- Received FDA communication related to previously announced IND clinical hold for MRT5201; [...]
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
27/02/2019
Initiation of Pivotal Phase 3 PRECISION-AF Clinical Trial Anticipated in Fourth Quarter WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a [...]
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China, Feb. 27, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd [...]
FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
—Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients — —Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU— —Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. [...]
CytomX Therapeutics Announces Full-Year 2018 Financial Results
27/02/2019
Company to Host a Conference Call Today, February 27, 2019, at 5:00 p.m. EST / 2:00 p.m. PST SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage [...]
Rafina Innovations Inc Comments on Recent Stock Volume and Price Increase
27/02/2019
GLASGOW, SCOTLAND, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc has been advised of a significant increase in the share price and trading volume of the Company's shares beginning Monday [...]
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), [...]
Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results
27/02/2019
BERKELEY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an important year for Aduro [...]

Pages